News

UroToday18h
SNMMI 2025: Clinical Protocols to Monitor Efficacy of 177Lu-PSMA Radiopharmaceutical Therapy in mCRPC
(UroToday.com) The 2025 SNMMI annual meeting featured a prostate cancer and dosimetry session and a presentation by Dr. Loic Djaileb discussing clinical protocols to monitor efficacy of 177 Lu-PSMA ...
UroToday1d
ASCO 2025: Prognostic Utility of ctDNA Before and After Trimodality Therapy (TMT) for Muscle Invasive Bladder Cancer
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Kidney and ...
UroToday1d
ASCO 2025: Avelumab + Sacituzumab Govitecan versus Avelumab Monotherapy as First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma: Interim Analysis ...
(UroToday.com) The 2025 ASCO annual meeting featured a urothelial carcinoma oral abstract session and a presentation by Dr. Jeannie Hoffman-Censits discussing an interim analysis from the JAVELIN ...
UroToday1d
SNMMI 2025: Evaluation of PSMA PET/CT Derived Predictors for Treatment Response to 177Lu-PSMA-617: Results from The U.S. Expanded-Access Program
Pre-therapeutic PSMA PET/CT information can be used to predict 177 Lu-PSMA-617 therapy response patterns and outcomes, with various quantitative and visual methods proposed. This study, presented at ...
UroToday1d
SNMMI 2025: Development of PSMA Targeting Radioligand 161Tb-LNC1011 for Prostate Cancer Theranostics
SNMMI annual meeting featured a radiotheranostics session and a presentation by Dr. Xuejen Wen discussing the development of PSMA targeting radioligand 161 Tb-LNC1011 for prostate cancer theranostics.
UroToday1d
SNMMI 2025: Prognostic Evaluation of an Artificial Intelligence (AI)-based Risk Score for Prostate Cancer on PSMA PET/CT
Dr. Kevin Leung presented an artificial intelligence-based risk score for the prognostic evaluation of prostate cancer patients using PSMA PET/CT imaging. Dr. Leung argued that improved survival ...
UroToday1d
ASCO 2025: Phase 3 AMPLITUDE Trial: Niraparib and Abiraterone Acetate plus Prednisone for Metastatic Castration-Sensitive Prostate Cancer Patients with Alterations in ...
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile.
UroToday1d
ASCO 2025: Multimodal Artificial Intelligence (MMAI) Model to Identify Benefit from 2nd-Generation Androgen Receptor Pathway Inhibitors (ARPI) in High-Risk Non-Metastatic ...
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile.
UroToday1d
ASCO 2025: Safety and Pharmacokinetics of Mevrometostat in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Prostate, ...
UroToday1d
ASCO 2025: Parp Up the Volume!: Combination Strategies in Advanced Prostate Cancer
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile.
UroToday1d
ASCO 2025: Discussion: Better Treatments, Better Selection: Improving Patient Outcomes in Localized Prostate Cancer
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile.